Consensus Virbac

Equities

VIRP

FR0000031577

Market Closed - Euronext Paris Other stock markets 11:35:13 2024-05-10 am EDT			5-day change	1st Jan Change
357 ^EUR	+0.28%		+0.42%	-0.70%

May. 03	VIRBAC : Virbac remains an attractive animal healthcare play
Apr. 17	VIRBAC : A healthy start to 2024; outlook re-iterated

Evolution of the average Target Price on Virbac

Price target over the last 5 years

History of analyst recommendation changes

2c35a1ef.Zzp-GjaVqup50DU96dZCUY_RpwNMlA6ysq57S-Lnqoo.NAkfVGStm5wgoXNI35MyJv23_lc23FzwyPsueK3V8N1UXUlFAKecoAGeUg~9be05e46bf6bbfaa4fb6cd4ebc983c85

Analyst Recommendations on Virbac

VIRBAC : Virbac remains an attractive animal healthcare play	May. 03
VIRBAC : A healthy start to 2024; outlook re-iterated	Apr. 17
VIRBAC : Oddo BHF maintains its recommendation on the stock	Mar. 21	CF
VIRBAC : Modest beat in Q4; 2024 outlook maintained	Jan. 18
Stifel Keeps Virbac at Hold, Boosts PT	Jan. 18	MT
VIRBAC : Stifel raises its target price	Jan. 18	CF
Virbac: one of the SBF120's top performers in 2023	Dec. 29	CF
VIRBAC : Onboarding some steady improvements	Dec. 22
Virbac: up sharply, a broker raises his target sharply	Dec. 20	CF
Oddo BHF Keeps Virbac at Outperform, Boosts PT	Dec. 20	MT
VIRBAC : Oddo BHF significantly raises its price target	Dec. 20	CF
VIRBAC : On course for a better-than-expected 2023 finish	Dec. 20
VIRBAC : Factoring in the improved 2023 outlook	23-10-26
VIRBAC : A rebound in Q3; outlook improved; markets jubilant	23-10-24
Oddo BHF Upgrades Virbac to Outperform from Neutral, Lifts PT	23-10-24	MT
VIRBAC : opinion upgraded by Oddo BHF after sales figures	23-10-24	CF
VIRBAC : H1 profitability pressure less severe than expected	23-10-03
Stifel Downgrades Virbac to Keep from Buy, Cuts PT	23-08-21	MT
Virbac: weighed down by a broker downgrade	23-08-21	CF
VIRBAC : Stifel downgrades its recommendation	23-08-21	CF
VIRBAC : In line Q2; markets coming to terms with the previously-moderated guidance	23-07-19
VIRBAC : Capacity constraints (temporary?) and a market slowdown weigh on near-term earnings	23-07-07
VIRBAC : A French animal healthcare giant investing for the future	23-06-06
VIRBAC : Q1 miss is no major reason to worry	23-04-18
Virbac: at half-mast after its quarterly trading update	23-04-18	CF

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

357 EUR

Average target price

368 EUR

Spread / Average Target

+3.08%

High Price Target

402 EUR

Spread / Highest target

+12.61%

Low Price Target

311 EUR

Spread / Lowest Target

-12.89%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Virbac

alphavalue	Abhishek Raval
Stifel Nicolaus
ODDO BHF

Ratings for Virbac

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar